XML 83 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   $ 176,319,000 $ 256,577,000 $ 212,958,000
Deferred revenue ($2,907 and $249 to a related party)   6,547,000 490,000  
Deferred revenue   138,474,000 99,449,000  
U.S./RoW [Member] | AstraZeneca Agreements [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   4,600    
Deferred revenue   137,500,000    
Drug Product Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   8,906,000 (36,324,000) 64,776,000
Estimated variable consideration transaction price     36,300,000  
Drug Product Revenue [Member] | AstraZeneca Agreements [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   4,625,000 0 0
Drug Product Revenue [Member] | API Shipment [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   4,000,000.0    
Drug Product Revenue [Member] | Japan [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized $ 8,200,000     64,800,000
Drug Product Revenue [Member] | Japan [Member] | Astellas Agreement [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   4,300,000 $ (36,300,000) $ 64,800,000
Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Deferred revenue ($2,907 and $249 to a related party)   1,400,000    
Deferred revenue   $ 4,600,000